Development and validation of the VISAGE AmpliSeq basic tool to predict appearance and ancestry from DNA.


Journal

Forensic science international. Genetics
ISSN: 1878-0326
Titre abrégé: Forensic Sci Int Genet
Pays: Netherlands
ID NLM: 101317016

Informations de publication

Date de publication:
09 2020
Historique:
received: 13 02 2020
revised: 28 05 2020
accepted: 08 06 2020
pubmed: 4 7 2020
medline: 13 7 2021
entrez: 4 7 2020
Statut: ppublish

Résumé

Forensic DNA phenotyping is gaining interest as the number of applications increases within the forensic genetics community. The possibility of providing investigative leads in addition to conventional DNA profiling for human identification provides new insights into otherwise "cold" police investigations. The ability of reporting on the bio-geographical ancestry (BGA), appearance characteristics and age based on DNA obtained from a crime scene sample of an unknown donor makes the exploration of such markers and the development of new methods meaningful for criminal investigations. The VISible Attributes through GEnomics (VISAGE) Consortium aims to disseminate and broaden the use of predictive markers and develop fully optimized and validated prototypes for forensic casework implementation. Here, the first VISAGE appearance and ancestry tool development, performance and validation is reported. A total of 153 SNPs (96.84 % assay conversion rate) were successfully incorporated into a single multiplex reaction using the AmpliSeq™ design pipeline, and applied for massively parallel sequencing with the Ion S5 platform. A collaborative effort involving six VISAGE laboratory partners was devised to perform all validation tests. An extensive validation plan was carefully organized to explore the assay's overall performance with optimum and low-input samples, as well as with challenging and casework mock samples. In addition, forensic validation studies such as concordance and mixture tests recurring to the Coriell sample set with known genotypes were performed. Finally, inhibitor tolerance and specificity were also evaluated. Results showed a robust, highly sensitive assay with good overall concordance between laboratories.

Identifiants

pubmed: 32619960
pii: S1872-4973(20)30109-5
doi: 10.1016/j.fsigen.2020.102336
pii:
doi:

Substances chimiques

Genetic Markers 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

102336

Subventions

Organisme : NHGRI NIH HHS
ID : UM1 HG008901
Pays : United States

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Catarina Xavier (C)

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: catarina.gomes@i-med.ac.at.

Maria de la Puente (M)

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria; Forensic Genetics Unit, Institute of Forensic Sciences, University of Santiago de Compostela, Spain.

Ana Mosquera-Miguel (A)

Forensic Genetics Unit, Institute of Forensic Sciences, University of Santiago de Compostela, Spain.

Ana Freire-Aradas (A)

Forensic Genetics Unit, Institute of Forensic Sciences, University of Santiago de Compostela, Spain.

Vivian Kalamara (V)

Department of Genetic Identification, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Athina Vidaki (A)

Department of Genetic Identification, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Theresa E Gross (T)

Institute of Legal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Andrew Revoir (A)

Metropolitan Police Service London, United Kingdom.

Ewelina Pośpiech (E)

Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland.

Ewa Kartasińska (E)

Central Forensic Laboratory of the Police, Warsaw, Poland.

Magdalena Spólnicka (M)

Central Forensic Laboratory of the Police, Warsaw, Poland.

Wojciech Branicki (W)

Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland; Central Forensic Laboratory of the Police, Warsaw, Poland.

Carole E Ames (C)

Metropolitan Police Service London, United Kingdom.

Peter M Schneider (P)

Institute of Legal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.

Carsten Hohoff (C)

Institut für Forensische Genetik GmbH, Münster, Germany.

Manfred Kayser (M)

Department of Genetic Identification, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.

Christopher Phillips (C)

Forensic Genetics Unit, Institute of Forensic Sciences, University of Santiago de Compostela, Spain.

Walther Parson (W)

Institute of Legal Medicine, Medical University of Innsbruck, Innsbruck, Austria; Forensic Science Program, The Pennsylvania State University, University Park, PA, USA. Electronic address: walther.parson@i-med.ac.at.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH